TY - JOUR
T1 - FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy
AU - Xiang, Zuo Lin
AU - Erasmus, Jeremy
AU - Komaki, Ritsuko
AU - Cox, James D.
AU - Chang, Joe Y.
N1 - Funding Information:
This research was supported in part by National Cancer Institute grants P01CA021239 and CA016672. We thank the thoracic radiation oncology and Proton Therapy Center teams at MD Anderson for their support; Dr. Kenneth R. Hess and Mark F. Munsell at the MD Anderson’s Department of Biostatistics for their statistical input; and Christine Wogan at MD Anderson’s Division of Radiation Oncology for editorial assistance.
PY - 2012/8/28
Y1 - 2012/8/28
N2 - Background: We studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC).Methods: Eighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent chemotherapy. PET/CT scans were available before (SUV1) and within 6 months after (SUV2) treatment. The predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression models.Results: Median survival time was 29.9 months. At 3 years, the local recurrence-free survival (LRFS) rate was 34.8%; distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%. Patients with SUV2 ≥3.6 (the median) had high rates of LR (p = 0.021). Of 12 clinicopathologic features evaluated in univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p <0.05). Multivariate analysis showed that KPS (p = 0.025) and SUV2 (p = 0.017) were independently prognostic for LRFS and that SUV1, SUV2, and KPS were independently prognostic for DMFS, PFS, and OS (p <0.05).Conclusions: SUV2 predicted LRFS, and SUV1 and SUV2 predicted DMFS, PFS, and OS, in patients with stage III NSCLC treated with concurrent chemotherapy and high-dose proton therapy.
AB - Background: We studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC).Methods: Eighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent chemotherapy. PET/CT scans were available before (SUV1) and within 6 months after (SUV2) treatment. The predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression models.Results: Median survival time was 29.9 months. At 3 years, the local recurrence-free survival (LRFS) rate was 34.8%; distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%. Patients with SUV2 ≥3.6 (the median) had high rates of LR (p = 0.021). Of 12 clinicopathologic features evaluated in univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p <0.05). Multivariate analysis showed that KPS (p = 0.025) and SUV2 (p = 0.017) were independently prognostic for LRFS and that SUV1, SUV2, and KPS were independently prognostic for DMFS, PFS, and OS (p <0.05).Conclusions: SUV2 predicted LRFS, and SUV1 and SUV2 predicted DMFS, PFS, and OS, in patients with stage III NSCLC treated with concurrent chemotherapy and high-dose proton therapy.
KW - Chemotherapy
KW - Non-small cell lung cancer
KW - PET/CT imaging
KW - Prognostic factors
KW - Proton therapy
KW - Standardized uptake value
UR - http://www.scopus.com/inward/record.url?scp=84865322776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865322776&partnerID=8YFLogxK
U2 - 10.1186/1748-717X-7-144
DO - 10.1186/1748-717X-7-144
M3 - Article
C2 - 22929048
AN - SCOPUS:84865322776
SN - 1748-717X
VL - 7
JO - Radiation Oncology
JF - Radiation Oncology
IS - 1
M1 - 144
ER -